About Onconova Therapeutics (NASDAQ:ONTX)
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Industry, Sector and Symbol
Trailing P/E Ratio-0.386281588447653
Forward P/E Ratio-0.38
Sales & Book Value
Annual Sales$5.55 million
Price / Sales3.74
Price / CashN/A
Book Value$0.76 per share
Price / Book1.41
Return on Equity-558.97%
Return on Assets-144.30%
Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions
What is Onconova Therapeutics' stock symbol?
Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."
When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?
Onconova Therapeutics shares reverse split on Tuesday, May 31st 2016. The 1-10 reverse split was announced on Friday, May 20th 2016. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 30th 2016. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Onconova Therapeutics' earnings last quarter?
Onconova Therapeutics Inc (NASDAQ:ONTX) announced its quarterly earnings results on Thursday, November, 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.73) by $0.02. The biopharmaceutical company earned $0.11 million during the quarter, compared to the consensus estimate of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. View Onconova Therapeutics' Earnings History.
When will Onconova Therapeutics make its next earnings announcement?
Where is Onconova Therapeutics' stock going? Where will Onconova Therapeutics' stock price be in 2018?
4 analysts have issued 1-year price objectives for Onconova Therapeutics' shares. Their forecasts range from $6.00 to $10.00. On average, they expect Onconova Therapeutics' stock price to reach $7.33 in the next twelve months. View Analyst Ratings for Onconova Therapeutics.
What are Wall Street analysts saying about Onconova Therapeutics stock?
Here are some recent quotes from research analysts about Onconova Therapeutics stock:
- 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (1/10/2018)
- 2. HC Wainwright analysts commented, "Rigosertib Expanding Footprint; Moving Forward With CRADA to Address RASopathies Moving forward on RASopathies with NCI. Onconova announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of rigosertib in pediatric cancer associated RASopathies. The NCI is to conduct and fund the majority of research, including preclinical laboratory studies and a clinical trial, whereas Onconova is expected to provide rigosertib and initial funding for non-clinical studies. The studies are slated to start in 2018. The NCI is to focus on RASopathy related cancers in pediatric patients, whereas Onconova is expecting to focus on Juvenile Myelomonocytic Leukemia (JMML). This event signifies the potential expansion of rigosertib use in a number of cancers and syndromes driven by RAS pathway hyperactivation." (1/4/2018)
- 3. Maxim Group analysts commented, "Onconova reported 3Q17 with a net loss of $7M and ended the period with $7.6M in cash. We forecast that Onconova will need to raise capital. The question then is, at what valuation and how much? The next catalyst for the company is the interim analysis of the INSPIRE pivotal phase 3 trial in Myelodysplastic Syndrome, which is expected in 4Q17. The interim analysis is dependent on reaching 88 events (deaths). Several scenarios could play out which we have profiled in prior notes and below. Conclusion: Good data will drive this company and set the stage to raise additional capital." (11/9/2017)
Who are some of Onconova Therapeutics' key competitors?
Who are Onconova Therapeutics' key executives?
Onconova Therapeutics' management team includes the folowing people:
- Michael M. B Hoffman, Chairman of the Board (Age 66)
- Ramesh Kumar Ph.D., President, Chief Executive Officer, Director (Age 59)
- Mark Guerin, Chief Financial Officer (Age 47)
- Steven M. Fruchtman M.D., Senior Vice President - Research and Development, Chief Medical Officer (Age 64)
- Manoj Maniar Ph.D., Senior Vice President - Product Development (Age 52)
- Henry S. Bienen Ph.D., Director (Age 76)
- Jerome E. Groopman M.D., Director (Age 63)
- Viren Mehta Ph.D., Director (Age 65)
- E. Premkumar Reddy Ph.D., Director (Age 71)
- Jack E. Stover CPA, Director (Age 64)
Who owns Onconova Therapeutics stock?
Onconova Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sabby Management LLC (5.21%) and 683 Capital Management LLC (4.32%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Institutional Ownership Trends for Onconova Therapeutics.
Who sold Onconova Therapeutics stock? Who is selling Onconova Therapeutics stock?
Who bought Onconova Therapeutics stock? Who is buying Onconova Therapeutics stock?
Onconova Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including 683 Capital Management LLC. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, E Premkumar Reddy, Mark Patrick Guerin and Ramesh Kumar. View Insider Buying and Selling for Onconova Therapeutics.
How do I buy Onconova Therapeutics stock?
Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Onconova Therapeutics' stock price today?
One share of Onconova Therapeutics stock can currently be purchased for approximately $1.07.
How big of a company is Onconova Therapeutics?
Onconova Therapeutics has a market capitalization of $20.78 million and generates $5.55 million in revenue each year. The biopharmaceutical company earns $-19,660,000.00 in net income (profit) each year or ($2.77) on an earnings per share basis. Onconova Therapeutics employs 23 workers across the globe.
How can I contact Onconova Therapeutics?
Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]
MarketBeat Community Rating for Onconova Therapeutics (ONTX)MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Onconova Therapeutics (NASDAQ:ONTX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.75||2.75||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$7.33||$7.33||$7.33||$8.00|
|Price Target Upside: ||326.36% upside||326.36% upside||283.94% upside||318.85% upside|
Onconova Therapeutics (NASDAQ:ONTX) Consensus Price Target History
Onconova Therapeutics (NASDAQ:ONTX) Analyst Ratings History
(Data available from 2/18/2016 forward)
Onconova Therapeutics (NASDAQ:ONTX) Earnings History and Estimates Chart
Onconova Therapeutics (NASDAQ ONTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.73)||($0.71)||$0.29 million||$0.11 million||View||N/A|
|8/14/2017||Q2 2017||($0.72)||($0.29)||$0.25 million||$0.32 million||View||N/A|
|5/15/2017||Q1 2017||($0.96)||($1.23)||$0.21 million||View||N/A|
|3/27/2017||Q4 2016||($0.54)||$0.17 million||View||N/A|
|11/14/2016||Q3 2016||($0.82)||($0.29)||$1.60 million||$1.70 million||View||N/A|
|5/11/2016||Q1||($0.19)||($0.27)||$1.34 million||$1.47 million||View||N/A|
|11/11/2015||Q3||($0.32)||($0.26)||$0.11 million||$1.62 million||View||N/A|
|8/13/2015||Q2||($0.56)||($0.41)||$0.11 million||$0.12 million||View||N/A|
|5/14/2015||Q1||($0.63)||($0.57)||$0.11 million||$0.11 million||View||N/A|
|8/13/2014||($0.89)||($0.77)||$0.56 million||$0.13 million||View||N/A|
|5/12/2014||($0.78)||($0.87)||$1.32 million||$0.45 million||View||N/A|
|3/10/2014||Q4 13||($1.07)||($0.68)||$1.07 million||$1.93 million||View||N/A|
|11/12/2013||Q3||($0.66)||($1.34)||$1.07 million||$1.12 million||View||Listen|
|9/6/2013||Q213||($5.21)||$0.22 million||$0.59 million||View||N/A|
Onconova Therapeutics (NASDAQ:ONTX) Earnings Estimates
Current Year EPS Consensus Estimate: $-2.82 EPS
Next Year EPS Consensus Estimate: $-1.87 EPS
Dividend History for Onconova Therapeutics (NASDAQ:ONTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Onconova Therapeutics (NASDAQ ONTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.30%
Institutional Ownership Percentage: 25.45%
Onconova Therapeutics (NASDAQ ONTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/8/2018||683 Capital Management, Llc||Major Shareholder||Buy||200,000||$1.04||$208,000.00|| |
|4/26/2017||E Premkumar Reddy||Director||Buy||119,048||$2.10||$250,000.80||385,832|| |
|4/26/2017||Mark Patrick Guerin||CFO||Buy||1,429||$2.10||$3,000.90||5,155|| |
|4/26/2017||Ramesh Kumar||Insider||Buy||23,810||$2.10||$50,001.00|| |
|2/21/2014||& Jane Hoffman 2013 De Michael||major shareholder||Buy||143,480||$8.47||$1,215,275.60||4,518,275|| |
|2/10/2014||Ramesh Kumar||CEO||Sell||33,543||$15.07||$505,493.01|| |
|2/3/2014||Ramesh Kumar||CEO||Sell||60,000||$15.05||$903,000.00|| |
|1/27/2014||Michael Hoffman||Director||Buy||57,295||$11.92||$682,956.40|| |
|11/22/2013||Michael Hoffman||Director||Buy||5,000||$14.39||$71,950.00|| |
|11/18/2013||E Premkumar Reddy||Director||Buy||5,000||$12.10||$60,500.00||1,278,718|| |
|11/15/2013||& Jane Hoffman 2013 De Michael||major shareholder||Buy||19,700||$11.99||$236,203.00||4,307,500|| |
|11/15/2013||Henry Bienen||Director||Buy||1,400||$12.17||$17,038.00||14,935|| |
|11/15/2013||Ramesh Kumar||CEO||Buy||1,100||$12.02||$13,222.00|| |
|7/30/2013||& Jane Hoffman 2013 De Michael||Major Shareholder||Buy||1,000,000||$15.00||$15,000,000.00|| |
|7/30/2013||Ramesh Kumar||CEO||Buy||6,667||$15.00||$100,005.00|| |
|7/30/2013||Thomas J Mckearn||Insider||Buy||3,333||$15.00||$49,995.00|| |
|7/30/2013||Viren Mehta||Director||Buy||16,667||$15.00||$250,005.00|| |
|7/25/2013||E Premkumar Reddy||Director||Buy||1,000||$22.72||$22,720.00|| |
Onconova Therapeutics (NASDAQ ONTX) News Headlines
|Onconova Therapeutics Announces Closing of $10 Million ... - GlobeNewswire (press release)|
globenewswire.com - February 13 at 6:00 AM
|Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Securities|
finance.yahoo.com - February 13 at 6:00 AM
|683 Capital Management, Llc Buys 200,000 Shares of Onconova Therapeutics Inc (ONTX) Stock|
www.americanbankingnews.com - February 12 at 6:46 PM
| Brokerages Anticipate Onconova Therapeutics Inc (ONTX) Will Post Earnings of -$0.71 Per Share|
www.americanbankingnews.com - February 12 at 11:30 AM
|Reviewing Syndax Pharmaceuticals (SNDX) and Onconova Therapeutics (ONTX)|
www.americanbankingnews.com - February 10 at 9:28 AM
|Onconova Therapeutics Announces Pricing of $8.7 Million ... - GlobeNewswire (press release)|
globenewswire.com - February 8 at 3:19 PM
|Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at ... - GlobeNewswire (press release)|
globenewswire.com - February 3 at 5:50 AM
|Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference|
finance.yahoo.com - February 2 at 3:20 PM
|Onconova Therapeutics Inc (ONTX) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - January 31 at 1:34 AM
|$310,000.00 in Sales Expected for Onconova Therapeutics Inc (ONTX) This Quarter|
www.americanbankingnews.com - January 28 at 4:42 AM
|Opiant Pharmaceuticals (OPNT) and Onconova Therapeutics (ONTX) Head to Head Comparison|
www.americanbankingnews.com - January 25 at 1:06 AM
|Onconova Therapeutics' (ONTX) "Buy" Rating Reiterated at HC Wainwright|
www.americanbankingnews.com - January 18 at 7:00 PM
|38 Stocks Moving In Wednesday's Mid-Day Session - Benzinga|
www.benzinga.com - January 18 at 4:14 PM
|Maxim Group Lowers Onconova Therapeutics (ONTX) to Hold|
www.americanbankingnews.com - January 17 at 3:12 PM
|Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis|
finance.yahoo.com - January 17 at 10:06 AM
|Onconova Therapeutics Is Looking to Spearhead the Next Drug Development Wave With Its Ongoing Trial|
finance.yahoo.com - January 12 at 4:34 PM
|Onconova Therapeutics Inc (ONTX) Expected to Announce Quarterly Sales of $410,000.00|
www.americanbankingnews.com - January 11 at 8:20 AM
|Onconova Therapeutics (ONTX) Upgraded to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - January 10 at 6:00 AM
|Zacks: Analysts Anticipate Onconova Therapeutics Inc (ONTX) to Post -$0.72 EPS|
www.americanbankingnews.com - January 9 at 11:36 AM
|Onconova Therapeutics (ONTX) Reports Cooperative Research and Development Agreement with the National Cancer Institute for Rigoserti|
www.streetinsider.com - January 4 at 4:44 PM
|Onconova Therapeutics (ONTX) Given a $6.00 Price Target at HC Wainwright|
www.americanbankingnews.com - January 4 at 12:40 PM
|Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the ... - GlobeNewswire (press release)|
globenewswire.com - January 4 at 10:07 AM
|Onconova Therapeutics Announces Cooperative Research and Development Agreement for Rigosertib with the National Cancer Institute|
finance.yahoo.com - January 4 at 10:07 AM
|Onconova Therapeutics to Present at Biotech Showcase in January - GlobeNewswire (press release)|
globenewswire.com - December 30 at 9:57 AM
|Onconova Therapeutics to Present at Biotech Showcase in January|
finance.yahoo.com - December 28 at 4:43 PM
|Comparing Optimer Pharmaceuticals (OPTR) & Onconova Therapeutics (ONTX)|
www.americanbankingnews.com - December 26 at 4:08 PM
|Onconova Therapeutics (ONTX) Downgraded to Sell at Zacks Investment Research|
www.americanbankingnews.com - December 25 at 9:26 AM
|Onconova Therapeutics Inc (ONTX) Expected to Announce Earnings of -$0.72 Per Share|
www.americanbankingnews.com - December 24 at 1:08 AM
|Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300|
finance.yahoo.com - December 21 at 10:13 AM
|Onconova Therapeutics (ONTX) PT Set at $6.00 by HC Wainwright|
www.americanbankingnews.com - December 19 at 11:10 AM
|Onconova Therapeutics Announces License and Collaborative Development Agreement with HanX Biopharmaceuticals for ON 123300, a Dual Inhibitor of CDK4/6 + ARK5|
finance.yahoo.com - December 19 at 10:15 AM
|Financial Survey: Ambit Biosciences (AMBI) and Onconova Therapeutics (ONTX)|
www.americanbankingnews.com - December 15 at 9:14 AM
|Onconova Presents Data on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2017 Meeting|
finance.yahoo.com - December 12 at 10:39 AM
|Onconova Therapeutics Inc (ONTX) Given Average Rating of "Hold" by Analysts|
www.americanbankingnews.com - December 12 at 3:46 AM
|Onconova Therapeutics Inc (ONTX): Are Analysts Right About The Drop In Earnings?|
finance.yahoo.com - December 9 at 10:12 AM
| Brokerages Expect Onconova Therapeutics Inc (ONTX) Will Post Quarterly Sales of $410,000.00|
www.americanbankingnews.com - December 8 at 12:58 PM
|-$0.72 EPS Expected for Onconova Therapeutics Inc (ONTX) This Quarter|
www.americanbankingnews.com - December 6 at 7:52 AM
| Onconova Therapeutics Inc (ONTX) Given $5.67 Average Target Price by Analysts|
www.americanbankingnews.com - December 4 at 8:54 AM
|Does Onconova Therapeutics Inc’s (ONTX) Past Performance Indicate A Weaker Future?|
finance.yahoo.com - November 30 at 4:40 PM
|Onconova Therapeutics to Present at the LD Micro Conference in December - GlobeNewswire (press release)|
globenewswire.com - November 21 at 9:03 AM
|Onconova Therapeutics to Present at the LD Micro Conference in December|
finance.yahoo.com - November 21 at 9:03 AM
|$410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter|
www.americanbankingnews.com - November 20 at 10:32 AM
|Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia|
finance.yahoo.com - November 18 at 10:40 AM
|Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting|
finance.yahoo.com - November 18 at 10:40 AM
|Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM)|
www.americanbankingnews.com - November 16 at 3:12 AM
|Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017|
finance.yahoo.com - November 14 at 6:30 AM
|Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha|
seekingalpha.com - November 11 at 8:33 AM
|Onconova Therapeutics, Inc. (ONTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS|
www.americanbankingnews.com - November 10 at 11:10 PM
|Onconova Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire (press release)|
globenewswire.com - November 10 at 2:57 PM
|Edited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMT|
finance.yahoo.com - November 10 at 2:57 PM
Onconova Therapeutics (NASDAQ:ONTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Onconova Therapeutics (NASDAQ:ONTX) Income Statement, Balance Sheet and Cash Flow Statement
Onconova Therapeutics (NASDAQ ONTX) Stock Chart for Sunday, February, 18, 2018